Medical Use – IMI Site Wed, 16 Jun 2021 13:16:05 +0000 en-US hourly 1 Medical Use – IMI Site 32 32 Dr Tony Holohan says antigen testing cannot be considered a ‘green light’ and excludes their use for international travel Wed, 16 Jun 2021 11:49:00 +0000

Chief Medical Officer Dr Tony Holohan reiterated his reservations about what he sees as the limitations of antigen testing, including their use in international travel.

r Holohan, who is appearing before the Oireachtas transport committee, will say that in some contexts they present risks to those involved in activities and cannot be used as a “green light”.

In his address, Dr Holohan said: “As the evidence evolves – and assuming that this evidence supports rapid antigenic testing – we are more than willing to support their further use when appropriately evaluated worldwide. real indicates that it can provide an additional benefit. in the response to the pandemic.

“Ultimately, however, based on the knowledge to date, the surest way to reopen the company, including to international travel, will be to continue to control the incidence of the disease through a series of measures. health issues that are continually reviewed, while advancing the national immunization program. to ensure that as many people as possible in the population are protected by vaccination.

He states that the epidemiological situation of Covid-19 in Ireland remains stable and currently gives rise to a largely positive outlook, despite a persistent level of uncertainty due to the threat of variants and while a significant proportion of the adult population does not. is not yet fully protected by vaccination.

He stresses that breaking the chains of transmission cannot be achieved by testing alone.

Ultimately, it depends on the extent to which appropriate individual and public health follow-up actions are implemented and supported by a broader and comprehensive public health response.

“That said, access to accurate and timely COVID-19 testing is an essential part of a multi-faceted response strategy that supports case identification and contact tracing, clinical management of cases, infection prevention and control, and disease surveillance, including emerging diseases. variants.

He adds that in this country to date, testing for the SARS-CoV-2 virus has been primarily based on a robust and agile PCR testing capability that has been built to around 175,000 tests per week.

PCR remains the most accurate and internationally recognized gold standard diagnostic test for SARS-CoV-2, he adds.

He will tell the committee that international evidence to date, including two recent major international publications from the Infectious Disease Society of America (IDSA) and the Royal Statistical Society (RSS) in the UK, the recent synthesis report on validation of the Covid-19 test published by the HSE and existing guidelines from the World Health Organization (WHO) and the European Center for Disease Prevention and Control (ECDC) all indicate that rapid antigenic tests are generally helpful better outcomes in symptomatic people and in settings of high disease prevalence, and worse in asymptomatic people in low prevalence settings.

“Based on existing evObviously, the use of rapid antigenic tests may be considered in high prevalence settings such as epidemics where the likelihood of individuals before testing for infection is high and where more rapidly available results can support PCR testing due to the ” early identification of cases and implementation of appropriate measures. follow-up public health actions.

“The HSE has already made rapid antigenic tests available for deployment in such scenarios, when deemed appropriate by local public health physicians.

“Rapid testing may also be considered in environments with a higher risk of COVID-19 transmission, such as may exist in meat processing plants. Substantial work has been carried out to evaluate the use of rapid antigenic tests in asymptomatic workers in this setting within the framework of strictly controlled processes and the HSE and the Ministry of Health have supported the piloting of rapid antigenic tests in factories of meat processing led by the Ministry of Agriculture, and the Navy.

“The HSE has also made available rapid antigenic tests for use in acute hospital settings.

“In addition, the Ministry of Health has supported the development of a collaborative pilot project by the Ministry of Higher and Higher Education, Research, Innovation and Science, SFI, HSE, HIQA and a number of third-level institutions to examine the potential applicability of different rapid testing approaches in third-level institutions and we look forward to reviewing the results of this study.

“Separately, the HSE is also implementing plans to pilot the use of rapid antigen testing in child care settings as well as a number of third level institutions.”

However, he states that “while there may be potential utility to be gained from using rapid tests in controlled environments and this may evolve over time, we still have a lot to learn about these tests and their use. reality – as opposed to hypothetical – advantages and limitations.

As the authors of the Royal Statistical Society in the UK report pointed out, the proper assessment of the adequacy of Covid-19 testing has been overlooked to date, with many tests coming to the market without proper assessment. real world and well-designed studies evaluating tests in the real world where they are used should become standard practice.

In particular, although pilots can be seen as ‘red light’ rapid testing activities, picking up additional cases in a timely manner and appropriately integrated into the larger framework of the public health response, great caution is advised. with regard to any development towards the use of rapid antigens. tests for “green light” or “enabling” testing activities, in particular without taking into account the current epidemiological situation. “

Source link

]]> 0
Discounts on drugs for insurers linked to higher costs for patients, especially the uninsured Tue, 15 Jun 2021 17:43:17 +0000

Health and Medicine | Press releases | Population health | Public health

June 15, 2021

Source link

]]> 0
UIC discovery could lead to new treatments for alcohol use disorders and depression Mon, 14 Jun 2021 23:40:00 +0000

A discovery by researchers at the University of Illinois at Chicago could lead to new treatments for people with alcohol use disorders and depression.

The study, “Transcriptomics identifies STAT3 as a key regulator of hippocampal and anhedonia gene expression during withdrawal from chronic alcohol exposure,” is published in the journal Translational Psychiatry by researchers at the UIC Center for Research on Alcohol in Epigenetics.

During long-term alcohol withdrawal, people often experience depression, which can cause them to start drinking again as a way to heal themselves. If we can deal with this aspect, we hope we can prevent people from relapsing. “

Amy Lasek, UIC Associate Professor of Psychiatry, Anatomy and Cell Biology, Faculty of Medicine and Study Author

Withdrawing from chronic alcohol use can often lead to depression. For this study, the researchers took post-mortem hippocampal samples from alcohol-withdrawn rats. The hippocampus is a region of the brain that plays a role in depression and cognitive function. The researchers performed RNA sequencing of all RNA transcripts in the hippocampus and looked for those that had been altered during alcohol withdrawal.

One of the RNA transcripts that has been altered produces a protein called STAT3. STAT3 is a transcription factor that controls the expression of many different genes, including immune response genes. Notably, several known genes regulated by STAT3 were also increased in the hippocampus during alcohol withdrawal, indicating that STAT3 could be a “major regulator” of several genes in the hippocampus during withdrawal.

The rats were treated during weaning with a compound which blocks the activity of STAT3. The anhedonia induced by weaning rats, or the inability to experience pleasure, was alleviated.

In addition, the researchers examined the same genes in human postmortem hippocampus samples from individuals with a medical diagnosis of alcohol use disorder, alcoholism. They found that STAT3 and its target genes were elevated in the postmortem hippocampus of deceased human subjects without alcohol in their system – either withdrawing or abstaining from alcohol – compared to samples from control subjects who did not have the disorder. of alcohol consumption. These results were surprisingly similar to the results found in the rat study.

“The studies in humans and rats are similar, which could mean that our results in rats can potentially be applied to humans. We have not done any treatment for people with alcohol use disorders, but we can see from the rat data that if we block it during weaning we can relieve depression, ”Lasek said.

Certain genes regulated by STAT3 are involved in the innate immune response in the brain. There is a known link between the overactive immune response and major depressive disorder, Lasek said.

“We know that chronic alcohol consumption can induce an immune response in the brain. By inhibiting STAT3, we believe that we dampen this overactive immune response by blocking the ability of STAT3 to increase the expression of these immune response genes during weaning, Lasek mentioned.

Lasek said inflammation in the brain is currently a hot topic of research and that further research could determine whether dampening the brain’s inflammatory response could treat psychiatric disorders.

Currently available antidepressants are not effective in reducing alcohol consumption. And other drugs available to treat alcohol use disorders are not universally effective. Further study for a better understanding of how STAT3 works could hopefully lead to more effective interventions for alcohol use disorders and associated depression, Lasek said.


Journal reference:

Chen, WY., et al. (2021) Transcriptomics identifies STAT3 as a key regulator of hippocampal and anhedonia gene expression during withdrawal from chronic alcohol exposure. Translational Psychiatry.

Source link

]]> 0
Global Normal Saline Solutions for Parenteral Use Market Growth Analysis 2021 – Baxter, Pfizer, B. Braun, ICU Medical – The Courier Sun, 13 Jun 2021 12:30:28 +0000

Global Parenteral Normal Salt Solutions Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 recently posted by highlights the many growth prospects dedicated to various industries, organizations, suppliers and associations offering several services. The report focused on the trends and key segments that are driving or preventing the growth of the global Normal Saline for Parenteral Use industry. The researchers also focused on individual growth trends in addition to their contribution to the overall market. A complete and clear overview of the market is written which is useful for many businesses.

First, the report describes the market overview, upstream, technology, price structure. The second part describes the global normal saline solutions for parenteral use market by major players, by application and by type. It also includes an analysis of the analysis of the competitive structure of the industry from the market returns of the province and a market analysis of the major players. Consideration is also given to the major challenges the business is currently facing and the likely future challenges that the business may face while operating in this market.

The goal of the researchers is to discover the sales, value and status of the industry internationally. There are several segments in the global normal saline solutions for parenteral use market and each segment is dependent on the other. In the research report, each segment has been detailed through growth analysis, risk analysis, and quantitative and qualitative research. The report also covers the new segmented products, applications and services which may impact the market.


NOTE: COVID-19 has a significant impact on businesses and the global economy in addition to serious public health implications. As the pandemic continues to evolve, there is a serious need for businesses to rethink and reconfigure their work packages for the changed world. Many industries around the world have successfully implemented management plans specifically for this crisis. This report offers you a detailed study of the impact of COVID-19 on the Normal Saline Solution for Parenteral Use market so that you can strategize.

The main players included in the report are:

Baxter, Pfizer, B. Braun, ICU Medical, Fresenius Kabi, Otsuka, Kelun Group, CR Double-Cran, SSY Group, Cisen Pharmaceutical, Denis Chem Lab Limited, Shree Krishnakeshav Laboratories, Pharmally International

The types covered in the industry are:

Soft bag, Plastic bottles, Glass bottles

The applications covered by the report are:

Intramuscular injection, Intravenous injection, Others

The geographic scope of this report includes:

North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy and rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia) East and Australia), America (Brazil, Argentina, Colombia and the rest of South America), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and the rest of the Middle East and Africa)


Additionally, report buyers will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales and other forecasts for the global parenteral normal saline solutions market during the period 2021 to 2026. The research report also provides detailed information about new trends that could define the development of the main segments in the years to come.

Ultimately, the report provides a conclusion which includes data breakdown and triangulation, consumer needs / change in customer preferences, research findings, market size estimate, source of data. These factors will increase overall activity.

Key questions answered in the report:

  • How has the rapidly changing business climate morphed into a significant development for the Global Normal Saline For Parenteral Use Market?
  • What are the basic elements that affect the development of the industry?
  • What are the key models continuously shaping the development of the global Normal Saline for Parenteral Use market?
  • What are the remarkable neighborhoods offering abundant market opportunities?

Customization of the report:

This report can be customized to meet customer requirements. Please connect with our sales team (, who will make sure you get a report that matches your needs. You can also contact our leaders at + 1-201-465-4211 to share your research needs.

Contact us
Brand Pierre
Head of Business Development
Call: + 1-201-465-4211
The Web:

Source link

]]> 0
Japan to criminalize cannabis use, but allow medical marijuana: expert panel report Sat, 12 Jun 2021 10:08:53 +0000

Dried cannabis and other confiscated items are seen in Building No. 3 of the Kudan Joint Government Office in the Chiyoda district of Tokyo on June 2, 2021. (Mainichi / Nana Hayashida)

TOKYO – Marijuana use will be criminalized as part of revisions to Japan’s cannabis control law, a panel of health ministry experts said in a report released on June 11.

The expert panel, led by Professor Tsutomo Suzuki of Shonan University of Medical Sciences, made the decision due to concerns over drug abuse by young people. Meanwhile, the panel also concluded that drugs derived from marijuana – currently restricted in Japan – should be allowed. The expert group will now begin deliberating on specific measures ahead of revisions to the Cannabis Control Act next year.

While the current law enacted in 1948 prohibits the possession and cultivation of cannabis, there is no criminal sanction for its use, such as smoking. The introduction of a provision banning the use of the drug had previously been postponed because farmers who cultivate the plant, which is used to make “shimenawa” hemp ropes for Shinto shrines and other uses, may l ‘inhale while they work.

In February, the Ministry of Health presented the results of tests to the panel of experts showing that no cannabinoids had been detected in the urine of farmers. In response, the panel concluded that “there are no reasonable grounds not to impose penalties on the use (of marijuana)”. The report raised the need for a sanction for drug use, in addition to the current sanctions for possession (imprisonment with work for five years or less) and culture (imprisonment with work for seven years or less).

During the discussions, three of the 12 panel members opposed the establishment of new criminal sanctions, expressing views such as “it goes against the global trend of focusing on support for recovery” and “Cannabis use cannot be said to cause social harm, and there are no factual grounds for execution (criminal penalties).” Other parties, including a drug addiction support group, had also called for “support” as opposed to “criminal punishment” and demanded that the provision be removed.

As a result, the expert group also mentioned efforts to prevent relapses, including drug addiction treatment, and improving support for social reintegration.

In 2020, 5,273 people were involved in cannabis-related cases recorded by the police and the drug control department of the Ministry of Health, among others, according to preliminary figures. The number of cases has doubled in the past five years to a new high, along with increasing internet use. People under 30 accounted for 65% of the total.

Meanwhile, the medical use of cannabis-derived drugs, which are currently restricted in the country, would be permitted under the report. The expert panel concluded that in addition to imports, the production and sale of medical cannabis should be allowed if authorized by the national government.

Medicinal cannabis has been approved in many countries, including the United States, and has been used to treat intractable epilepsy and relieve cancer pain, but its import and use is currently banned in Japan under the United States Act. cannabis control. A growing number of doctors and others in Japan were demanding that the ban on use be lifted.

The expert group reviewed the current cannabis law, which imposes regulations based on parts of the cannabis plant, and found it appropriate to adjust them to focus the restrictions on a substance called tetrahydrocannabinol (THC), a hallucinogen. . The panel called for a review of the law to organize distribution and management structures, including a licensing system, to allow the use of marijuana for medical purposes.

(Japanese original by Hidenori Yazawa, Medical News and Lifestyle Department)

Source link

]]> 0
An Update on Medical Marijuana | Opinions Fri, 11 Jun 2021 21:00:00 +0000

The IM26 passed by voters last fall legalized medical marijuana in South Dakota. Although the measure itself goes into effect on July 1, that does not automatically mean that those who wish to use medical cannabis will be able to visit a local dispensary and purchase it from July 1. The measure itself contains several specific dates of implementation. various parts of the law. It also creates an oversight committee to monitor implementation and make recommendations to the Legislature and the Department of Health on possible improvements.

At its meeting in early June, the LRC executive board appointed the 14 members of the IM26 oversight committee. Several residents of District 24 are on this committee, including Fort. Pierre Resident Brian Doherty, Pierre Police Captain Bryan Walz, DCI Deputy Director Brian Zeeb, AG Staff Member Mathew Templar and Health Secretary Kim Malsam-Rysdon.

By October 29, the Department of Health is expected to adopt rules to establish and implement criteria related to patient cards, medical marijuana establishments and related matters governing medical cannabis. The rule making process is very detailed and can take several months. The Ministry of Health is currently collecting feedback from stakeholders and is working to finalize a set of rules in July. The ministry plans to have a public rules hearing in August, before heading to the Legislative Assembly’s Rules Review Committee in September.

By November 18, the ministry should be able to issue registry identification cards to eligible patients and caregivers.

Patients with a qualifying debilitating medical condition should consult their physician, who will determine whether the patient is likely to derive therapeutic or palliative benefit from the medical use of cannabis. Although doctors are not authorized to prescribe medical cannabis, they can certify that, in their professional opinion, the patient is likely to benefit from the use of cannabis.

Patients with this certification can apply to the Ministry of Health for an identification card from the registry. These cards will be valid for up to one year. The patient can then take the card to a licensed dispensary to purchase medical marijuana. Only licensed dispensaries will be able to sell medical cannabis; pharmacies will not be able to sell the product. Additionally, since medical cannabis is not considered a prescription, it will be subject to state and local taxes.

The Department of Health has created a web page ( to keep the public informed about the state’s medical marijuana program. The page includes an FAQ section to help provide additional information on the topic. Also, feel free to contact me with any questions, and I will work to find answers for you.

Source link

]]> 0
Dartmouth medical school drops online cheating cases against students Thu, 10 Jun 2021 22:51:17 +0000

Dartmouth Geisel School of Medicine said it was dropping an investigation into online cheating that led the school to falsely accuse some students, allegations that sparked an uproar among faculty, alumni and experts in technology.

In March, Dartmouth accused 17 students of cheating based on a review of some online activity data on Canvas – a popular learning management system where professors post homework and students submit their work – during remote exams. The school quickly dropped seven of the cases after at least two students argued that administrators mistook Canvas’s automated activity for human cheating.

Now Dartmouth is also dropping allegations against the remaining 10 students, some of whom have faced expulsion, suspension, course failures and misconduct notes on their academic records that could have derailed their careers. medical.

“I have decided to dismiss all the honor code accusations,” Duane A. Compton, the dean of the medical school, said Wednesday evening in an email to the Geisel community, adding that the academic records of the students would not be affected. “I apologized to the students for what they went through. “

Dartmouth’s decision to dismiss the charges follows a New York Times review of the software, which found that student devices could automatically generate Canvas activity data even when no one was using them. Dartmouth’s practices have been condemned by some former students as well as professors from other medical schools.

A spokesperson for Dartmouth said the school could not comment further on the dropping of the charges due to confidentiality concerns. The school’s agreements with the students who had been charged are not yet final, and the students did not immediately return requests for comment.

The cheating investigation has turned the Ivy League pastoral campus into a national battleground against escalating school surveillance during the pandemic.

Join Michael Barbaro and the “The Daily” team as they celebrate students and teachers who are ending a year like no other with a special live event. Meet the students of Odessa High School, which was the subject of a Times audio documentary series. We’ll even get some noise with a performance by the award-winning Odessa Marching Band Drum Line and a special celebrity opening keynote.

While many universities, including Dartmouth, require students to use special software that locks their devices during remote exams, Geisel has gone further by using a second system, Canvas, to retroactively track student activity during exams. remote examinations without their knowledge. This was unusual because Canvas was not intended as a forensic tool.

Tech experts said Dartmouth’s use of Canvas raised questions. While some students may have cheated, these experts said, it would be difficult for school administrators to distinguish cheating from non-cheating based on the type of Canvas data snapshots used by Dartmouth.

The case was also notable for the Dartmouth proceedings after the students were charged.

Some of the accused students said Dartmouth crippled their ability to defend themselves. They were given less than 48 hours to respond to the charges, were not given full data logs for the exams, and were asked to plead guilty despite denying cheating or having only two minutes to do so. make their case in online hearings, according to interviews with six of the students and a review of documents.

In an interview in April, Dr Compton said the school’s methods of identifying possible cheating were fair and valid. Administrators, he said, provided the accused students with all the data on which the cheating accusations were based. He denied that the student affairs office advised those who said they didn’t cheat to plead guilty.

In his email on Wednesday, he took on a different tone.

“As we look to the future, we need to ensure the fairness of our Code of Honor review process, especially in an academic environment that includes more distance learning,” wrote Dr Compton. “We will learn from it and we will do better. “

Source link

]]> 0
ICMR Approves Meril’s Self-Use Rapid Antigen Test Kit for COVID-19 Thu, 10 Jun 2021 06:05:45 +0000

The test kit is priced at 250 and will be available as a single pack, with additional purchase options including a 3, 5 and 25 test pack.

Meril Diagnostics of Gujarat has announced that its self-use rapid antigen test kit for COVID-19, CoviFind, has received approval from the Indian Council for Medical Research (ICMR).

“This locally researched and developed test kit can reliably detect the SARS-CoV-2 virus in infectious individuals and therefore can be used to test symptomatic individuals and immediate contacts of confirmed coronavirus cases, as specified by the recent ICMR guidelines, ”the company said in a statement.

“The CoviFind test for the home self-test is very effective in people with a medium to high viral load, especially in detecting infection in the case of people more likely to transmit the disease to others”, adds the communicated.

The test also delivers results quickly, providing results within 15 minutes, he said.

The test kit has no specific storage or refrigeration requirements, which makes it easy and easy to distribute, he added.

The test kit is priced at 250 and will be available as a single pack, with additional purchase options including a 3, 5 and 25 test pack.

Each test kit is equipped with test materials including a test device, a sterile nasal swab, and a pre-filled buffer tube with a stopper.

No additional instrumentation is required. The kit will also contain an Instructions for Use (IFU), detailing the step-by-step procedure on administration, handling and disposal after use of the test kit, as well as a disposable bag.

The self-use test is to be used with the company’s official home test mobile app, “CoviFind App”, which will be available for download from the Google Play Store and Apple App Store once that the product will be marketed.

The test kit will be available in two weeks at retail pharmacies, online pharmacies and through e-commerce platforms including Amazon and Flipkart, with the company trying to speed up the process, he said.

It will also maintain a website dedicated to direct orders of the test kit by individuals and institutions.

“By making fast and reliable antigen tests available to everyone in a convenient format, Meril’s CoviFind test kit will facilitate early detection, isolation, treatment and contact tracing,” said Sanjeev Bhatt, vice -Senior President, Corporate Strategy, Meril Diagnostics.

“This will limit the spread of infections, contributing to the country’s continued efforts to quell the second wave of the pandemic. We are committed to producing our locally developed self-use test in high volumes to meet India’s testing needs, ”he added.

Source link

]]> 0
Clinical trial examines effectiveness of HIV and drug addiction care delivery through mobile clinics Wed, 09 Jun 2021 17:16:00 +0000

A clinical trial is underway in five US cities to determine whether the delivery of integrated health services through mobile clinics can improve HIV and substance abuse outcomes in people with opioid use disorders who inject drugs. If effective, mobile clinics could serve as an innovative strategy to expand access to care and provide uninterrupted treatment to this underserved population that is tackling public health crises related to drug addiction and HIV.

According to the Centers for Disease Control and Prevention, about 1 in 10 new HIV diagnoses in the United States are attributed, in whole or in part, to injection drug use. Additionally, high rates of injection drug use in communities have been linked to HIV outbreaks. Although injection drug use is not limited to injecting opioids – a class of drugs that includes heroin and fentanyl – these drugs have a high rate of use among key populations in this new study . Almost all study participants are expected to inject opioids at the time of enrollment. Substance use and dependence can also have a disruptive effect in a person’s life that may make it difficult to take daily medications, including antiretroviral therapy (ART) for the treatment of HIV or pre-exposure prophylaxis ( PrEP) for HIV prevention.

The study aims to address these challenges by providing holistic health services delivered in accessible mobile clinics. These integrated services include safe and effective medications for opioid use disorders (buprenorphine) and overdose reversal (naloxone or Narcan), syringe services where available, HIV testing. , antiretroviral therapy for treatment of HIV, PrEP for prevention of HIV, tests for hepatitis and sexually transmitted infections. (STI) and primary care services. Mobile clinics will be set up in residential areas deemed accessible to people living with HIV who inject opioids. In contrast, many community organizations are located throughout downtown and shopping areas which can be difficult to access for people with limited transportation options.

Too often, drug treatment and life-saving HIV care are delivered by a patchwork of health professionals under many different roofs, presenting major access challenges for people who use opioids and drugs. other drugs. By providing these services through a welcoming one-stop-shop and meeting people where they are, we hope to find a way to more effectively treat people with HIV and substance use disorders. “

Nora D. Volkow, MD, Director of NIDA

The study, known as INTEGRA or HPTN 094, is funded by the National Institute on Drug Abuse (NIDA) and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), both of which are part of the National Institutes of Health. INTEGRA is led by the NIH-funded HIV Prevention Trials Network (HPTN) at locations in Los Angeles, New York, Houston, Philadelphia and Washington, DC

“People are more than their HIV status or their diagnosis of addiction, but these factors make it difficult to access care,” Steven Shoptaw, Ph.D., president of the INTEGRA protocol and director of the Center for Behavioral and Addiction Medicine, told the University of California, Los Angeles. “The COVID-19 pandemic has restricted access to medical care for so many people. At the same time, the intertwined epidemics of opioid addiction and HIV continued to take their toll. Now is the time to test innovative strategies to connect our most vulnerable populations. effective and integrated care.

Nabila El-Basel, Ph.D., university professor at Columbia University School of Social Work, is co-chair of the INTEGRA protocol.

The study team aims to recruit 860 participants with opioid use disorders who inject drugs. Equal numbers of participants will be randomly assigned to receive care through a single mobile clinic or multiple community agencies. The latter group, which reflects the current standard of care, will serve as the control arm of the study.

For 26 weeks, participants in both parts of the study will have access to trained peer navigators to help coordinate and facilitate care visits, during which they will be offered routine health services based on identified needs. during the initial assessment. At weeks 26 and 52, researchers will assess drug use for opioid use disorders, viral suppression rates in HIV-positive participants, use of PrEP in HIV-negative participants, use of opioids and other substances based on participant self-report and urine. screenings, drug overdose events and new diagnoses of HIV, SARS-CoV-2 (the virus that causes COVID-19), hepatitis C and bacterial STIs, among other health measures in both groups.

Investigators will also analyze the cost-effectiveness and logistical value of providing care through mobile clinics versus community agencies. INTEGRA’s results are expected in 2025.

Learn more about HPTN 094 / INTEGRA, or “A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care” by visiting and using study ID NCT04804072 and

Source link

]]> 0
Vireo Health Prepares Expansion of Johnstown Growing Facility Wed, 09 Jun 2021 03:12:43 +0000

JOHNSTOWN – Local marijuana producer Vireo Health is expanding to capitalize on the expected growth in the medical and recreational uses of its products in the state.

“As it stands, New York is the biggest opportunity for Vireo Health,” company CEO Dr. Kyle Kingsley said in an investor video presentation released Tuesday.

The company is exercising its $ 1.3 million option to purchase 97 acres alongside its existing cultivation and production facility at Tryon Industrial Park in Johnstown, where it plans to add up to 200,000 square feet of production space.

Kingsley told the Daily Gazette on Tuesday that state regulations for the production and sale of recreational marijuana were not complete, but the company has enough confidence in the market to move forward now and it will therefore be ready when the rules are over.

This may mean that the structures are being built but not immediately completed and filled with equipment inside, he said. The work will be done in consultation with the regulators.

“We intend to expand our facilities quite significantly,” Kingsley said, hoping that there will be a marked shortage when the legal market opens in New York.

Another big boost for Vireo is that New York has legalized the sale of whole flower cannabis for medical use, Kingsely said. Consumers prefer this form, he said, but until now New York has limited medical marijuana products to extracts, not the whole flower.

“I think it’s going to be the biggest blow to the arm in New York,” he added.

Meanwhile, Vireo is looking for a larger space for their only dispensary in the Capital Region, currently located on Fuller Road in Colony.

And the public can see a name change on the dispensaries at some point: On Tuesday, Vireo Health International announced that it was changing its name to Goodness Growth Holdings. Vireo Health will be the multi-state cannabis subsidiary.

Also on Tuesday, Goodness Growth announced that another affiliate, Resurgent Biosciences, will move into the psychedelic medicine space, with intellectual property development and clinical research, but no actual manufacture or distribution of psychedelics.

Kingsley said he was initially skeptical of psychedelics, but they have shown remarkable success in treating conditions such as depression.

He said regulatory approval for medical psychedelics would likely be decades away, but predicted it would come during his lifetime. “It’s going to be transformative,” he said.

Hurdles remain for Vireo, which last month reported a loss of $ 7 million for the first quarter of 2021:

  • Because the federal government classifies marijuana as a Schedule 1 drug like LSD, heroin and ecstasy – no medical use and high risk of abuse – Vireo and other companies cannot operate across state borders and achieve economies of scale, whether for recreational or medical purposes. . Kingsley is hoping the current Washington leadership will remove marijuana from Schedule 1.
  • Because there is little research on medical marijuana that provides knowledge and advice on specific dosages and effects, many doctors remain reluctant to prescribe it to patients.
  • The regulatory framework New York created for the production and sale of recreational marijuana remains an unknown.

Despite these factors, Kingsley remains optimistic.

Vireo finished 2019 and 2020 in the red but went from $ 30 million in revenue to $ 49 million. With major regulatory changes coming to Minnesota, New Mexico and New York, he expects cash flow to turn positive in the first half of 2022 and expects revenue of $ 140 million to $ 180 million for the whole of 2022.

More from The Daily Gazette:

Categories: Business, News

Source link

]]> 0